Job creations
Boston, New York, San Diego and San Francisco are the typical spots that people refer to when they think about biotech hotspots in the United States. But don’t discount New Jersey.
Evotec is now a more powerful player in the infectious disease sector following the signing of its three-month-old deal to integrate Sanofi’s anti-infectives unit, including the majority of Sanofi’s infectious disease research portfolio and initiatives into its organization.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
In late March, Novo Nordisk broke ground on a new manufacturing facility in rural Clayton, North Carolina.
In anticipation of marketing approval in Europe, Gilead Sciences has leased a 117,000 square-foot facility in The Netherlands to manufacture and deliver Yescarta, its CAR-T product, to patients across Europe.
Vyriad, based in Rochester, Minnesota, announced it is building out its facility in 25,000 square feet of space it is leasing on the IBM Campus in Rochester.
The Information Technology & Innovation Foundation recently published a report diving into the U.S.’s trade deficits in the life sciences industry worldwide and steps that can be made to keep the biopharma and medical device industries competitive globally.
As Biogen turns 40 years old, some biotech insiders and analysts seem to be concerned that the Boston-based pharmaceutical company has too many eggs in one developmental basket.
Pfizer launched a new ad that celebrates diversity in its employment.
PRESS RELEASES